Business Context and Reporting Period
Company: Amarin Corporation plc (AMRN)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Amarin is a pharmaceutical company focused on cardiovascular health, primarily commercializing VASCEPA (icosapent ethyl) in the U.S. and VAZKEPA in Europe. The company operates in a single reportable segment. In June 2025, the company executed an exclusive long-term license and supply agreement with Recordati for VAZKEPA in 59 European countries, triggering a global restructuring plan.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2025 |
Six Months Ended June 30, 2024 |
|---|---|---|---|
| Total Revenue, Net | $72,741 | $114,757 | $124,010 |
| Product Revenue, Net | $46,617 | $87,652 | $102,670 |
| Licensing & Royalty Revenue | $26,124 | $27,105 | $21,340 |
| Gross Margin | $50,362 (69.2%) | $75,491 (65.8%) | $74,673 (60.2%) |
| Operating Loss | $(15,985) | $(32,742) | $(14,107) |
| Net Loss | $(14,139) | $(29,836) | $(8,431) |
| Diluted EPS | $(0.03) | $(0.07) | $(0.02) |
| Cash & Cash Equivalents | $147,877 (as of June 30, 2025) | ||
| Short-term Investments | $150,827 (as of June 30, 2025) | ||
| Total Liquidity | $298.7 million (as of June 30, 2025) | ||
| Debt | $0 (No outstanding debt) |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue for the six months ended June 30, 2025, decreased 7% to $114.8 million compared to $124.0 million in the prior year. This was driven by a 15% decline in U.S. product revenue ($72.2M vs. $91.9M) due to generic competition and the loss of a major PBM. However, licensing revenue increased 27% to $27.1 million, primarily due to a $25.0 million upfront payment from the new Recordati agreement.
- Restructuring Charges: The company incurred $22.8 million in restructuring expenses in the first half of 2025, compared to zero in the prior year. This charge relates to a global restructuring plan announced in June 2025 to eliminate commercial roles in European operations following the Recordati partnership.
- Profitability: The net loss widened significantly to $29.8 million for the six months ended June 30, 2025, compared to $8.4 million in the prior year, largely attributable to the one-time restructuring charge.
- Cash Flow: Net cash provided by operating activities improved to $4.1 million in the first half of 2025, reversing a $15.4 million outflow in the same period of 2024.
Guidance, Outlook, and Risks
- Strategic Shift: Following the Recordati agreement, Amarin has exited direct commercialization of VAZKEPA in 59 European countries. The company expects annual cost savings of approximately $70.0 million from the restructuring, primarily from eliminating European commercial roles.
- U.S. Market Dynamics: The company faces continued generic competition in the U.S. for the MARINE indication. Market share for VASCEPA in the U.S. decreased to approximately 42% in the first half of 2025 from 57% in the prior year. Branded prescriptions decreased by 26% year-over-year.
- Liquidity Outlook: Management believes current cash and short-term investments ($298.7 million) are sufficient to fund operations for at least one year. The company has a $50.0 million share repurchase program authorized but has not commenced repurchases to date.
- Key Risks:
- Recordati Execution: Future revenue depends on Recordati's ability to successfully commercialize VAZKEPA in Europe and secure reimbursement.
- Generic Competition: Continued erosion of U.S. market share and pricing pressure from multiple generic entrants.
- Regulatory & Reimbursement: Success in Europe relies on securing national reimbursement in various countries, which is uncertain and time-consuming.
- Legal Proceedings: Ongoing patent litigation regarding the REDUCE-IT indication against Hikma, currently pending Supreme Court review.
Investor Verification Checklist
- Recordati Agreement Terms: Verify the specific royalty rates, milestone thresholds, and supply obligations under the new Recordati EU Licensing Agreement.
- Restructuring Progress: Monitor the actual realization of the projected $70.0 million in annual cost savings and the timeline for the reduction in force.
- U.S. Market Share Trends: Track Symphony Health prescription data to assess if the decline in branded VASCEPA prescriptions stabilizes or accelerates.
- Inventory Levels: Review the composition of the $210.8 million inventory balance, specifically the portion approved for North America (47%) versus long-term inventory, to assess obsolescence risk.
- Legal Status: Monitor the outcome of the Hikma patent infringement case pending at the U.S. Supreme Court, which impacts the REDUCE-IT indication protection.